Avamis (fluticasone furoate) - new intranasal corticosteroid for the treatment of allergic rhinitis



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Рассмотрены свойства флутиказона фуроата (ФФ) - нового интраназального глюкокортикоида для лечения аллергического ринита (АР) у взрослых и детей с 2 лет. Отличительными особенностями ФФ являются высокая и длительная противовоспалительная активность наряду с низкой биодоступностью. Клинические исследования показали, что одновременно с назальными препарат стабильно уменьшает выраженность глазных симптомов АР и имеет благоприятный профиль безопасности. Усовершенствованная система доставки ФФ позволяет повысить приверженность пациентов к терапии. Применение ФФ значительно повышает качество жизни больных АР, восстанавливает дневную активность, ночной сон, работоспособность, снижает медико-социальное бремя заболевания и затраты пациентов на его лечение за счет уменьшения потребности в других лекарственных средствах.

About the authors

A V Emelianov

St. Petersburg Medical Academy for Postgraduate Education

St. Petersburg Medical Academy for Postgraduate Education

References

  1. Bousquet J., van Cavuwenberge P., Khaltaev N. et al. Allergic rhinitis and its impact on asthma (ARIA). Pocket Guide-WHO. 2001,23 р.
  2. Bousquet J., Khaltaev N., Cruz A. et al. Allergic rhinitis and its impact on asthma (ARIA) update 2008 (in collaboration with World Health Organization, GA2LEN and AllerGen). Allergy. 2008, v. 63, suppl. 86, p. 8-160.
  3. Hellgen J., Cervin A., Nordling S. et al. Allergic rhinitis and the common cold - high cost to society. Allergy, 2009, epub doi: 10.1111/j.l398-9995.2009.02269.x.
  4. Canonica GW., Bousquet J., Mullol J. et al. A survey of the burden of allergic rhinitis in Europe. Allergy. 2007, v. 62, suppl. 85, p. 17-25.
  5. Gueron В., Demoly P., Mullol J. et al. Quality of life and work productivity in allergic rhinitis patients suffering from both nasal and ocular symptoms - an observational, cross sectional study in four countries in Europe. Allergy. 2009, v. 64, suppl. 90, No. 866.
  6. GueronB., Demoly P., Mullol J. etal. Impact of ocular symptoms on resource utilization and work productivity in management of AR- an observational, cross sectional study in four countries in Europe. Allergy. 2009, v. 64, suppl. 90, No. 867.
  7. Baroody F.M., Foster K.A., Markaryan A. et al. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol. 2008, v. 100, No. 1, p. 194-199.
  8. Naclerio R., Pinto I., deTineo M., Baroody F.M. Elucidating the mechanism underlying the ocular symptoms associated with allergic rhinitis. Allergy Asthma Proc. 2008, v. 29, No. 1, p. 24-28.
  9. Naclerio R.M., Hadley I.A., Stoloff S., Nelson H.S. Patient and physician perspectives on the attributes of nasal allergy medications. Allergy Asthma Proc. 2007, v. 28, p. S11-S17.
  10. Salter M., Biggadike K., Matthews J.L. et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in vivo model of respiratory inflammatory disease. Am. I. Physiol Lung. Cell. Mol. Physiol. 2007, v. 293, p. 660-667.
  11. Hughes S., ShatdlowPC, HollisFJ. etal. Metabolism and disposition of fluticasone furoate, an enhanced-affinity glucocorticoid, in humans. Drug Metabolism and Disposition. 2008, v. 36, No. 11, p. 2337-2344.
  12. Bryson H.M., Faulds D. Intranasal fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in allergic rhinitis. Drugs. 1992, v. 43, No. 5, p. 760-775.
  13. Daley-YatesPT, Baker R.C. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations. Br. I. Clin. Pharm. 2001, v. 51, No. 1, p.103-105.
  14. Daley-Yates P.T., Kunka R.L., Yin Y et al. Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur. I. Clin. Pharm. 2004, v. 60, No. 4, p. 265-268.
  15. Allen A., Down G., Newland A. et al. Absolute bioavailability of intranasal fluticasone furoate inhealthy subjects. Clin. Ther. 2007, v. 29, No. 7, p. 1415-1420.
  16. Baumann D., Bachert C, Hogger P. Dissolution in nasal fluid, retention and anti-inflammatory activity fluticasone furoate in human nasal tissue ex vivo. Clin. Exp. Allergy. 2009, v. 39, p. 1540-1550.
  17. Martin B.G.,Rathner PH., Hampbel EC. et al. Optimal dose selection of fluticasone furoate nasal spray for the treatment of seasonal allergic rhinitis in adults and adolescents. Allergy Asthma Proc. 2007, v. 28, p. 216-225.
  18. Scadding G., Keith PK. Fluticasone furoate nasal spray consistently and significantly improves both the nasal and ocular symptoms of seasonal allergic rhinitis: a review of the clinical data. Expert Opin Pharmacother. 2008, v. 9, No. 15, p. 2707-2715.
  19. Meltzer E.O., Dee I., Tripathy I. et al. Efficacy and safety of once-daily fluticasone furoate nasal spray in children with seasonal allergic rhinitis treated for 2 wk. Pediatr. Allergy Immunol. 2009, v. 20, No. 3, p. 279-286.
  20. Baroody E/M., Shenaq D., DeThieno M. etal. Fluticasone furoate nasal spray reduces the naso-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. I. Allergy Clin. Immunol. 2009. v. 123, No. 6, p. 1342-1348.
  21. Keith P., Scadding G. Are intranasal corticosteroids all equally consistent in managing ocular symptoms of seasonal allergic rhinitis? Curr. Med. Res. Opinion. 2009, v. 25, No. 8, p. 2021-2041.
  22. Maspero J.F, Rosenblut A., Finn A. Jr. et al. Safety and efficacy of fluticasone furoate in pediatric patients with perennial allergic rhinitis. Otorhingol Head Neck Surg. 2008, v. 138, No. 1, p. 30-33.
  23. Nathan R.A., Berger W., Yang W. et al. Effect of once-daily fluticasone furoate nasal spray on nasal symptoms in adults and adolescents with perennial allergic rhinitis. Ann. Asthma Immunol. 2008, v. 100, No. 5, p. 497-505.
  24. Vasar M., Houle P.A., Douglass J.A. et al. Fluticasone furoate nasal spray: effective monotherapy for symptoms of perennial allergic rhinitis in adults/adolescents. Allergy Asthma Proc. 2008, v. 29, No. 3, p. 313-321.
  25. Meltzer E.O., Tripathy I., Maspero J.F. etal. Safety and tolerability of fluticasone furoate nasal spray once daily in padiatric patients aged 6-11 years with allergic rhinitis: subanalysis of three randomized, double-blind, placebo-controlled, multicentre studies. Clin. Drug Investig. 2009, v. 29, No. 2, p. 79-86.
  26. Rosenblut A., Bardin P.G., Muller B. et al. Long term safety of fluticasone furoate nasal spray in adults and adolescents with perennial rhinitis. Allergy. 2007, v. 62, p. 1071-1077.
  27. Gradman J., Caldwell M.F, Wolthers O.D. A 2-week, crossover study to investigate the effect of fluticasone furoate nasal spray on short-term growth in children with allergic rhinitis. Clin. Ther. 2007, v. 29, No. 8, p. 1738-1747.
  28. Garris C, Shan M., D'Souza A., Stanford R. Comparison of corticosteroid nasal sprays in relation to concomitant use and cost of other prescription medications to treat allergic rhinitis symptoms. Retrospective cohort analysis of pharmacy claim data. Clin. Drug Invet. 2009. v. 29, No. 8, p. 515-526.
  29. Berger W., Godfrey J.W., Slater A. Intranasal corticosteroids: the development of a drug delivery divice for fluticasone furoate as potential step toward improved compliance. Expert Opin Drug Deliv. 2007, v. 4, No. 6, p. 689-701.
  30. Meltzer E.O., Stahlman J.E., Leflein J. et al. Preferences of adult patients with allergic rhinitis for the sensory attributes of fluticasone furoate versus fluticasone propionate nasal sprays: a randomized, multicenter, double-blind, single-dose, crossover study. Clin. Ther. 2008, v. 30, No. 2, p. 271-279.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2009



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies